Clinical Trial Update: Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating infliximab and basiliximab for steroid-refractory acute graft-versus-host disease; study terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Gvh Disease
• Steroid Refractory Gvhd

Drugs mentioned

• Basiliximab (basiliximab)
• Infliximab (infliximab)

Snippet

Sponsor: Nationwide Children's Hospital | Conditions: Graft Versus Host Disease, Steroid Refractory GVHD | Phase 2 | Status: TERMINATED | Results posted: 2019-04-05